Log in
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Dynamic quotes 
  1. Homepage
  2. Equities
  3. United Kingdom
  4. London Stock Exchange
  5. AstraZeneca PLC
  6. News
  7. Summary
    AZN   GB0009895292


SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

AstraZeneca : Norway to ease COVID-19 curbs, vaccine rollout may be delayed

04/13/2021 | 10:29am EDT
FILE PHOTO: A general view of the Norwegian central bank, where Norway's sovereign wealth fund is situated, in Oslo

OSLO, April 13 (Reuters) - Norway will start to unwind some restrictions related to the COVID-19 pandemic and allow more people to gather from Friday, Prime Minister Erna Solberg said on Tuesday.

However, the country's vaccine rollout risks being delayed by up to almost three months if it does not go ahead and use AstraZeneca and Johnson & Johnson's shots, the Norwegian Institute of Public Health said.

Norway will say on Thursday whether it will resume using the AstraZeneca vaccine, on hold since a small number of younger inoculated people developed a combination of blood clots, bleeding and a low platelet count, some of whom later died.

Johnson & Johnson, meanwhile, said it was delaying the roll-out of its vaccine to Europe as U.S. health agencies recommended pausing its use after six women under 50 given the shot developed rare blood clots.

Norway has had some of Europe's lowest rates of infections and deaths since the start of the pandemic, but imposed stricter measures after a rapid increase in hospitalisations in March triggered by more contagious variants of the coronavirus.

"The infection numbers are now down. Hospitalisations are fewer. The measures look to have had an effect," Solberg told a news conference.

As a result, Norwegians will from Friday again be allowed to receive up to five guests in private homes, up from two currently, and restaurants can serve alcohol under certain conditions.

A maximum of 100 people will be allowed to attend indoor events in for example theaters and sports arenas, provided there are fixed seating arrangements, and groups of up to 200 people can attend outdoor events.

The easing of rules at the national level will not affect those in areas of the Nordic country where the infection rate is the highest, such as in the Oslo capital region, Solberg said.

Non-essential stores remain closed in the Oslo area, and restaurants there are still only allowed to provide takeaway service, and some schools remain shut.

Line Vold, head of infection control and emergency preparedness at the Institute of Public Health, predicted between eight and 12 weeks of delay in vaccinating Norwegians if the AstraZeneca and Johnson & Johnson shots were shunned.

"It will be mainly for the younger groups (in the population). We will be done with vaccination of people in risk groups," she told the same news conference.

The government has said earlier it estimates that everyone aged 18 or older will have been offered their first vaccine shot by the end of July.

(Editing by Mark Heinrich)

© Reuters 2021
Stocks mentioned in the article
ChangeLast1st jan.
ASTRAZENECA PLC 1.02% 7494 Delayed Quote.1.28%
S&P GSCI GOLD INDEX 0.40% 1035.5149 Delayed Quote.-6.57%
All news about ASTRAZENECA PLC
11:31aASTRAZENECA  : UNICEF To Receive 65 Million Doses Of AstraZeneca's COVID-19 Vacc..
11:17aEuropean ADRs Move Sharply Lower in Tuesday Trading
11:14aJOHNSON & JOHNSON  : EMA Says Benefits of Johnson & Johnson's COVID-19 Vaccine O..
11:06aEXCLUSIVE : UNICEF says AstraZeneca supply problems outside India resolved
10:33aTHE LATEST : EU regulator OKs warning labels for J&J vaccine
10:06aASTRAZENECA  : Egypt's Health Minister Discusses Manufacturing Sputnik V Locally..
09:35aEU Agency Says Benefits of J&J Covid-19 Vaccine Outweigh Risks but Calls for ..
06:47aFACTBOX-Some countries limit AstraZeneca vaccine use, EU findings on J&J shot..
06:41aJ&J stands ready to roll out COVID-19 vaccine in Europe as regulators weigh r..
05:58aUNIVERSITY OF LIVERPOOL : Study outlines mechanism behind rare blood clots linke..
More news
Financials (USD)
Sales 2021 30 703 M - -
Net income 2021 4 602 M - -
Net Debt 2021 11 692 M - -
P/E ratio 2021 28,8x
Yield 2021 2,75%
Capitalization 136 B 136 B -
EV / Sales 2021 4,82x
EV / Sales 2022 4,20x
Nbr of Employees 76 100
Free-Float 95,8%
Duration : Period :
AstraZeneca PLC Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends ASTRAZENECA PLC
Short TermMid-TermLong Term
Income Statement Evolution
Mean consensus BUY
Number of Analysts 25
Average target price 129,40 $
Last Close Price 103,78 $
Spread / Highest target 59,9%
Spread / Average Target 24,7%
Spread / Lowest Target -9,25%
EPS Revisions
Managers and Directors
Pascal Soriot Chief Executive Officer & Executive Director
Marc Pierre Jean Dunoyer Chief Financial Officer & Executive Director
Leif Valdemar Johansson Non-Executive Chairman
Menelas N. Pangalos EVP-Biopharmaceuticals Research & Development
Pam P. Cheng Executive VP-Operations & Information Technology
Sector and Competitors
1st jan.Capitalization (M$)
JOHNSON & JOHNSON3.37%428 315
ROCHE HOLDING AG0.42%292 008
PFIZER, INC.4.78%217 158
NOVARTIS AG-3.24%199 551
MERCK & CO., INC.-5.06%196 581